Novartis India Ltd Upgraded to Hold on Technical Improvements and Long-Term Growth

Technical Trends Drive Upgrade

The primary catalyst behind the upgrade to a Hold rating is the marked improvement in Novartis India’s technical grade, which has moved from mildly bullish to bullish. Weekly and monthly MACD indicators both signal bullish momentum, reinforcing positive price action over multiple timeframes. The daily moving averages also support this trend, showing consistent upward movement.

Additional technical tools such as Bollinger Bands confirm bullishness on both weekly and monthly charts, while the On-Balance Volume (OBV) indicator shows a weekly bullish trend, suggesting accumulation by investors. However, some caution remains as the monthly Relative Strength Index (RSI) and KST indicators are bearish, indicating potential short-term overbought conditions or momentum loss.

Despite these mixed signals, the overall technical picture has improved sufficiently to justify the upgrade, signalling that the stock’s price action is gaining strength and could sustain upward movement in the near term.

Valuation and Quality Assessment

Novartis India currently trades at ₹1,034.10, down 1.79% on the day, with a 52-week high of ₹1,099.90 and a low of ₹747.60. The stock’s Price to Book (P/B) ratio stands at 3.3, which is considered expensive relative to its Return on Equity (ROE) of 12.5%. This valuation suggests that the market is pricing in growth expectations, but investors should be mindful of the premium compared to peers.

The company’s PEG ratio of 2.1 indicates that earnings growth is not fully aligned with the stock price appreciation, signalling a moderately stretched valuation. Despite this, the stock’s long-term returns have been impressive, outperforming the Sensex and BSE500 indices significantly over multiple periods. For instance, Novartis India has delivered a 34.05% return over the past year compared to the Sensex’s decline of 3.48%, and a 73.77% return over three years versus the Sensex’s 26.81%.

However, the company’s quality grade remains at Hold with a Mojo Score of 51.0, reflecting a balanced view of its fundamentals. The previous Sell rating was downgraded due to concerns over recent financial performance and valuation, but the current assessment recognises the company’s strong market position and growth potential.

Financial Trend: Mixed Quarterly Results but Strong Operating Growth

Novartis India’s recent quarterly financial performance has been disappointing, with Q3 FY25-26 reporting a 36.8% decline in PAT to ₹16.09 crores and a 15.35% fall in PBT excluding other income to ₹20.90 crores. The company’s debtors turnover ratio for the half-year is at a low 7.28 times, indicating slower collection efficiency.

Despite these short-term setbacks, the company remains net-debt free, a significant positive in the pharmaceutical sector where capital intensity can be high. Moreover, operating profit has grown at an impressive annualised rate of 57.68%, underscoring robust underlying business momentum.

This strong operating growth supports the long-term investment thesis, even as recent quarterly results warrant caution. The company’s ability to generate healthy cash flows without leverage enhances its financial stability and resilience.

Market Performance and Investor Sentiment

Novartis India has outperformed the broader market consistently over various time horizons. Year-to-date, the stock has gained 32.75%, compared to a 9.06% decline in the Sensex. Over one year, the stock returned 34.05%, significantly ahead of the Sensex’s negative 3.48%. Even over five and ten years, the stock’s returns of 59.12% and 39.65% respectively have been competitive, though the Sensex’s 10-year return of 202.64% remains substantially higher.

Interestingly, domestic mutual funds hold a negligible 0.01% stake in Novartis India. Given their capacity for detailed research and on-the-ground analysis, this low ownership may reflect reservations about the company’s valuation or recent financial performance. This limited institutional interest could impact liquidity and price discovery in the stock.

Summary and Outlook

The upgrade of Novartis India Ltd’s rating from Sell to Hold reflects a balanced reassessment of its investment merits. The technical indicators have improved markedly, signalling renewed momentum and potential for price appreciation. Meanwhile, the company’s long-term operating profit growth and net-debt-free status provide a solid fundamental base.

However, recent quarterly earnings declines and an expensive valuation relative to ROE temper enthusiasm. The stock’s PEG ratio above 2.0 and limited institutional ownership suggest that investors should approach with measured expectations. The Hold rating appropriately reflects this cautious optimism, recognising both the company’s strengths and the risks ahead.

Investors considering Novartis India should monitor upcoming quarterly results closely, alongside technical signals, to gauge whether the bullish momentum sustains. Given the company’s strong long-term returns and improving technical profile, it remains a stock worthy of attention within the Pharmaceuticals & Biotechnology sector, particularly for those favouring small-cap exposure with growth potential.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today